Liquid biopsy in colorectal cancer – the time has come?
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
Advanced genetic testing is largely inaccessible to cancer patients across Europe
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Early-phase data from targeting HER3 with ADC are encouraging
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Extended safety information and PROs data support key trial results in metastatic breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Breast cancer leads the way in ADC therapy
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
Challenging past dogma in breast cancer research – what's next?
In her keynote lecture, recipient of the ESMO Breast Cancer Award 2023, Prof. Sara A. Hurvitz talks of the need to challenge accepted paradigms to progress clinical research
Cemiplimab survival improvements in NSCLC are durable
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
New insights into targeting KRAS G12C mutations in NSCLC
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment